{
    "address": "Scheelevagen 27",
    "city": "Lund",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W1987A107",
    "description": "Cantargia AB is a holding company, which engages in the development of antibody-based cancer treatment. The company is headquartered in Lund, Skane and currently employs 19 full-time employees. The company went IPO on 2015-03-17. The firm is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.",
    "employeeTotal": "19.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2015-03-17",
    "isin": "SE0006371126",
    "logo": "",
    "marketCapitalization": 2414.645,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Cantargia AB",
    "phone": "46462756260.0",
    "sedol": "BVGBXG0",
    "shareOutstanding": 100.192737,
    "state": "SKANE",
    "ticker": "CANTA.ST",
    "weburl": "http://www.cantargia.com"
}